Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder

Completed · Phase 4

Conditions studied: Insomnia, Generalized Anxiety Disorder

In brief

To determine the safety and efficacy of eszopiclone as adjunctive therapy in the treatment of insomnia in patients with insomnia related to Generalized Anxiety Disorder. All subjects will receive an approved anxiolytic agent and will be randomized to nightly therapy with either eszopiclone or placebo.

Key facts

Study ID
NCT00235508
Run by
Sumitomo Pharma America, Inc.
People needed
420
Starts
2005-06-01
Expected to finish
2006-04-01
Last updated by the study team
2012-02-22

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.